Lundbeck
Klaus A. Rytved, PhD, ERT, is a seasoned professional in toxicology and preclinical development with extensive experience spanning over two decades. Currently serving as a Senior Principal Scientist at Lundbeck since January 2025, Klaus previously held key positions at LEO Pharma, where contributions included safety assessment and predictive toxicology as Principal Scientist. Earlier roles include Programme Manager at NeuroSearch A/S, overseeing preclinical project management, and Safety Pharmacologist at Novo Nordisk A/S, responsible for safety pharmacology study execution. Klaus's academic foundation includes a Ph.D. in Cellular Physiology from Københavns Universitet and additional advanced studies at the University of Cambridge and University of Surrey.
This person is not in any teams
Lundbeck
43 followers
Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at disease areas such as depression, schizophrenia, Parkinson’s disease and Alzheimer’s disease.